231 related articles for article (PubMed ID: 34121659)
21. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
[TBL] [Abstract][Full Text] [Related]
22. Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
Cristea S; Sage J
J Thorac Oncol; 2016 Aug; 11(8):1233-1241. PubMed ID: 27133774
[TBL] [Abstract][Full Text] [Related]
23. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
24. RAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites.
Hollenhorst PC
Small GTPases; 2012; 3(3):154-8. PubMed ID: 22653334
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer.
Wang H; Yu Z; Huo S; Chen Z; Ou Z; Mai J; Ding S; Zhang J
Int J Biochem Cell Biol; 2018 Jan; 94():98-106. PubMed ID: 29208568
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
29. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.
Li Y; Takahashi M; Stork PJS
J Biol Chem; 2013 Sep; 288(38):27646-27657. PubMed ID: 23893412
[TBL] [Abstract][Full Text] [Related]
30. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC
Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768
[TBL] [Abstract][Full Text] [Related]
31. Genetic predictors of MEK dependence in non-small cell lung cancer.
Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
[TBL] [Abstract][Full Text] [Related]
32. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Coco S; Truini A; Alama A; Dal Bello MG; Venè R; Garuti A; Carminati E; Rijavec E; Genova C; Barletta G; Sini C; Ballestrero A; Boccardo F; Grossi F
Target Oncol; 2015 Sep; 10(3):393-404. PubMed ID: 25341405
[TBL] [Abstract][Full Text] [Related]
33. Histone acetyltransferase p300 mediates the upregulation of CTEN induced by the activation of EGFR signaling in cancer cells.
Chang CC; Liu YC; Lin CH; Liao YC
Biochem Biophys Res Commun; 2021 Jan; 534():53-58. PubMed ID: 33310188
[TBL] [Abstract][Full Text] [Related]
34. ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers.
Martin-Vega A; Earnest S; Augustyn A; Wichaidit C; Gazdar A; Girard L; Peyton M; Kollipara RK; Minna JD; Johnson JE; Cobb MH
bioRxiv; 2023 Jun; ():. PubMed ID: 37398419
[TBL] [Abstract][Full Text] [Related]
35. Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways.
Zhang B; Tao F; Zhang H
Mol Med Rep; 2018 Apr; 17(4):4899-4908. PubMed ID: 29393472
[TBL] [Abstract][Full Text] [Related]
36. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
37. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
Wang M; Kern AM; Hülskötter M; Greninger P; Singh A; Pan Y; Chowdhury D; Krause M; Baumann M; Benes CH; Efstathiou JA; Settleman J; Willers H
Cancer Res; 2014 May; 74(10):2825-34. PubMed ID: 24648348
[TBL] [Abstract][Full Text] [Related]
38. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
Vicent S; Garayoa M; López-Picazo JM; Lozano MD; Toledo G; Thunnissen FB; Manzano RG; Montuenga LM
Clin Cancer Res; 2004 Jun; 10(11):3639-49. PubMed ID: 15173070
[TBL] [Abstract][Full Text] [Related]
39. Nodal signaling promotes a tumorigenic phenotype in human breast cancer.
Kirsammer G; Strizzi L; Margaryan NV; Gilgur A; Hyser M; Atkinson J; Kirschmann DA; Seftor EA; Hendrix MJ
Semin Cancer Biol; 2014 Dec; 29():40-50. PubMed ID: 25073112
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]